熱門資訊> 正文
泰坦制药宣布纳斯达克不合规通知
2024-11-28 05:22
- Titan Pharmaceuticals (NASDAQ:TTNP) was notified by Nasdaq that it failed to file its Q3 report on time, violating listing requirements.
- The company has until January 21, 2025, to submit a plan to regain compliance. If Nasdaq accepts the plan, then Nasdaq may grant an exception of until May 19, 2025, to regain compliance.
- Nasdaq also notified the company that it no longer meets audit committee requirements following Brynner Chiam’s appointment as acting principal executive officer and acting principal financial officer.
- Titan Pharmaceuticals intends to appoint an additional independent director to the board and the audit committee.
- Source: Press Release
More on Titan Pharmaceuticals
- Financial information for Titan Pharmaceuticals
推薦文章
蘇媽出馬穩投資者信心：AMD(AMD.US)AI芯片需求強勁 市場增量高達千億級美元
財報前瞻丨騰訊Q2營收有望躍升11%！遊戲業務引領增長，AI商業化迎來突破
非農大修預示美國經濟拐點？又一聯儲官員拉響警報 降息呼聲漸高
新股申購 | 「減肥藥概念」 銀諾醫藥-B一手入場費3773.68港元，引入邁富時等基石投資者
驚現「烏龍指」？美債昨夜盤中閃崩引各方猜測 最詭異的是……
華盛早報丨芯片和半導體突發！特朗普：100%關税，蘋果等將被豁免；又有美聯儲高官放鴿
外盤頭條：特朗普對印度額外徵收25%關税，非農修正或預示美國經濟轉折
蘋果宣佈再投1000億美元支持美國製造 股價創近三個月來最大單日漲幅
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
